The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL

Duvelisib (also known as IPI-145) is an oral, dual inhibitor of phosphatidylinositol 3-kinase δ and γ (PI3K-δ,γ) being developed for treatment of hematologic malignancies. PI3K-δ,γ signaling can promote B-cell proliferation and survival in clonal B-cell malignancies, such as chronic lymphocytic leuk...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Blood
Glavni autori: Flinn, Ian W., Hillmen, Peter, Montillo, Marco, Nagy, Zsolt, Illés, Árpád, Etienne, Gabriel, Delgado, Julio, Kuss, Bryone J., Tam, Constantine S., Gasztonyi, Zoltán, Offner, Fritz, Lunin, Scott, Bosch, Francesco, Davids, Matthew S., Lamanna, Nicole, Jaeger, Ulrich, Ghia, Paolo, Cymbalista, Florence, Portell, Craig A., Skarbnik, Alan P., Cashen, Amanda F., Weaver, David T., Kelly, Virginia M., Turnbull, Barry, Stilgenbauer, Stephan
Format: Artigo
Jezik:Inglês
Izdano: American Society of Hematology 2018
Teme:
Clinical Trials and Observations
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6284216/
https://ncbi.nlm.nih.gov/pubmed/30287523
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2018-05-850461
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items